Literature DB >> 16791713

Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.

Maciej Owecki1, Jerzy Sowiński.   

Abstract

Management of Graves' ophthalmopathy includes high-dose glucocorticoids. Glucocorticoids may have many side effects, and therefore their use should always be carefully considered. Here we present the case of a woman who received high doses of methylprednisolone (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by myocardial infarction on the fifth day of treatment. Before the myocardial infarction, the patient was in good condition, normotensive, non-diabetic, non-obese. Except hypothyroidism after radioiodine treatment (euthyroid under substitutional therapy), she suffered from no other diseases. There had been one episode of chest discomfort in her past history. We conclude that myocardial infarction may develop in patients treated with high-dose glucocorticoids for Graves' ophthalmopathy, and increased blood pressure may herald this complication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791713     DOI: 10.1007/s11096-006-9013-y

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  9 in total

Review 1.  Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Authors:  Bellur S Prabhakar; Rebecca S Bahn; Terry J Smith
Journal:  Endocr Rev       Date:  2003-12       Impact factor: 19.871

2.  Effects of allopurinol, propranolol and methylprednisolone on infarct size in experimental myocardial infarction.

Authors:  C H Shatney; D J MacCarter; R C Lillehei
Journal:  Am J Cardiol       Date:  1976-03-31       Impact factor: 2.778

3.  Sudden death after methylprednisolone pulse therapy.

Authors:  T S Bocanegra; M O Castañeda; L R Espinoza; F B Vasey; B F Germain
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

4.  Methylprednisolone treatment in acute myocardial infarction. Effect on regional and global myocardial function.

Authors:  J Osher; T W Lang; S Meerbaum; K Hashimoto; J C Farcot; E Corday
Journal:  Am J Cardiol       Date:  1976-03-31       Impact factor: 2.778

Review 5.  Methylprednisolone interventions in myocardial infarction: a controversial subject.

Authors:  Y M LeGal; L L Morrissey
Journal:  Can J Cardiol       Date:  1990-11       Impact factor: 5.223

6.  Effects of methylprednisolone on the ischemic damage in patients with acute myocardial infarction.

Authors:  J E Madias; W B Hood
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

7.  Effects of high-dose intravenous methylprednisolone on circulation in humans.

Authors:  R S Smith; D J Warren
Journal:  Transplantation       Date:  1983-04       Impact factor: 4.939

8.  Use of methylprednisolone in patients following acute myocardial infarction. Hemodynamic and metabolic effects.

Authors:  R J Henning; H Becker; J L Vincent; L Thijs; E Kalter; M H Weil
Journal:  Chest       Date:  1981-02       Impact factor: 9.410

9.  Methylprednisolone as an intervention following myocardial infarction. The Solu-Medrol Sterile Powder AMI Studies Group.

Authors: 
Journal:  J Int Med Res       Date:  1986       Impact factor: 1.671

  9 in total
  7 in total

1.  Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.

Authors:  M Riedl; E Kolbe; E Kampmann; I Krämer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-01-10       Impact factor: 4.256

2.  Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.

Authors:  Piotr Miskiewicz; Justyna Milczarek-Banach; Tomasz Bednarczuk; Grzegorz Opolski; Renata Glowczynska
Journal:  Int J Mol Sci       Date:  2018-09-26       Impact factor: 5.923

Review 3.  Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application.

Authors:  Jan Längericht; Irene Krämer; George J Kahaly
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-14       Impact factor: 3.565

4.  Methylprednisolone-Induced Symptomatic Sinus Bradycardia in a Multiple Sclerosis Patient: A Case Report.

Authors:  Mohammed A Miqdad; Abdullah Mohamad; Fawaz Ali; Abdul Rahman Mourad; Abdullah Alamri
Journal:  Cureus       Date:  2022-01-20

5.  Dexamethasone Associated ST Elevation Myocardial Infarction Four Days after an Unremarkable Coronary Angiogram-Another Reason for Cautious Use of Steroids: A Case Report and Review of the Literature.

Authors:  Mohamed Shokr; Ahmed Rashed; Kusum Lata; Ashok Kondur
Journal:  Case Rep Cardiol       Date:  2016-07-18

Review 6.  Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy.

Authors:  Dorota Walasik-Szemplińska; Grzegorz Kamiński; Iwona Sudoł-Szopińska
Journal:  Thyroid Res       Date:  2019-12-23

7.  Acute bilateral cerebral infarction in the presence of neuromyelitis optica spectrum disorder: A case report.

Authors:  Zi-Yi Wang; Meng Wang; Jiao-Jiao Guo; Yan-Lu Gao; Xue-Fan Yu
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.